Viking Global Investors’s Intellia Therapeutics NTLA Stock Holding History

Viking Global Investors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,569,545	Closed	-$58.5M	–	93
2023 Q1	$58.5M	Sell	1,569,545 -451,865	-22%	-$17.7M	0.27%	60
2022 Q4	$70.5M	Buy	2,021,410 +132,343	+7%	+$6.29M	0.35%	56
2022 Q3	$106M	Sell	1,889,067 -339,316	-15%	-$21M	0.49%	53
2022 Q2	$115M	Sell	2,228,383 -240,377	-10%	-$12.2M	0.53%	50
2022 Q1	$179M	Buy	2,468,760 +889,224	+56%	+$75.3M	0.73%	38
2021 Q4	$187M	Buy	1,579,536 +300,005	+23%	+$37.6M	0.54%	52
2021 Q3	$172M	Buy	1,279,531 +304,439	+31%	+$46.1M	0.47%	60
2021 Q2	$158M	Buy	+975,092	New	+$75.9M	0.48%	49

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Viking Global Investors's NTLA Position: Q2 2023 in Review

Viking Global Investors sold out of Intellia Therapeutics (NTLA) in Q2 2023, closing a stake of 1,569,545 shares — an estimated $58.5M sold.

Viking Global Investors first reported a position in NTLA in Q2 2021 and held it in 8 quarters. The position peaked at $187M in Q4 2021. 290 funds tracked by Wall St. Rank hold NTLA as of Q2 2023.

Viking Global Investors reported no remaining Intellia Therapeutics position as of Q2 2023 after selling out during the quarter.
Viking Global Investors sold 1,569,545 Intellia Therapeutics shares in Q2 2023, an estimated $58.5M.
Viking Global Investors first reported a position in Intellia Therapeutics in Q2 2021 and held it in 8 quarters.
Viking Global Investors's Intellia Therapeutics position peaked at $187M in Q4 2021.
290 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2023.

Based on Viking Global Investors's 13F filing for Q2 2023, filed 14 Aug 2023.